Pilot studies were conducted to evaluate the @entity137 and efficacy of two relatively marrow-sparing chemotherapy regimens in the treatment of advanced or progressive @entity2826 . Chemotherapy regimens consisted of @entity1732 (10 mg/m2), @entity1891 (1.4 mg/m2, 2 mg maximum) and @entity632 ( @entity632 ) at either 10 mg/m2 (Group I) or 20 mg/m2 (Group II). The therapy was given intravenously, every 2 weeks, until intolerable @entity137 or maximum antitumor response. Thirty-three @entity1 were treated. Although the @entity1 populations were similar regarding pretreatment prognostic factors, the @entity1 were not assigned randomly to these two treatment regimens. Major responses (complete or partial remission) were attained in 79% of the cases. The treatment-related @entity137 consisted of mild to moderate @entity390 , hair loss, and @entity1897 . @entity236 consisted primarily of @entity1398 (less than 1000/mm3) which occurred in a third of the @entity1 . Variables significantly associated with shorter survival included hemoglobin (less than 10 g/dl), low Karnofsky performance status (less than 70%), and @entity353 . @entity1292 occurred in the majority of cases during administration of chemotherapy, and were most likely related to severe cell-mediated @entity1200 and low @entity404 -positive lymphocyte counts.

Advanced acquired immune deficiency syndrome-related XXXX . Results of pilot studies using combination chemotherapy.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['Adriamycin', 'doxorubicin'] @entity2826 :: ('MESH:D012514', 'Disease') :: ["epidemic Kaposi's sarcoma"] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral sensory neuropathy'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune dysfunction'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity236 :: ('MESH:D001855', 'Disease') :: ['Bone marrow suppression'] @entity1292 :: ('MESH:D009894', 'Disease') :: ['Opportunistic infections']
@entity2826 :: (MESH:D012514,Disease) :: ['Kaposi's sarcoma']
